ZONN.BE - REPROS THERAP.NEW DL-,001

Berlin - Berlin Delayed Price. Currency in EUR
0.302
-0.022 (-6.790%)
At close: 8:08AM CET
Stock chart is not supported by your current browser
Previous Close0.324
Open0.302
Bid0.312 x 0
Ask0.344 x 0
Day's Range0.302 - 0.302
52 Week Range0.132 - 1.816
Volume2,000
Avg. Volume0
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press6 days ago

    Repros Therapeutics reports 3Q loss

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $304,000 in the period. The company's shares closed at 41 cents. ...

  • Associated Press3 months ago

    Repros Therapeutics reports 2Q loss

    The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...

  • Associated Press6 months ago

    Repros Therapeutics reports 1Q loss

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $7,000 in the period. In the final minutes of trading on Tuesday, ...

  • Associated Press8 months ago

    Repros Therapeutics reports 4Q loss

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $5,000 in the period. For the year, the company reported that ...

  • Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
    Zacks8 months ago

    Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

    Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

  • Repros to Meet with the FDA for Phase III Proellex Program
    Zacks11 months ago

    Repros to Meet with the FDA for Phase III Proellex Program

    Repros (RPRX) announced that it has requested a meeting with the FDA to discuss requirements for phase III development of Proellex.

  • How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers
    Insider Monkey11 months ago

    How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers

    Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]

  • 24/7 Wall St.11 months ago

    7 Companies That Destroyed Shareholders Last Week

    The S&P 500 and Dow are pushing new highs as 2016 comes to a close. While the post-election tailwind has been incredibly strong, there are still companies holding back this rally.

  • 24/7 Wall St.11 months ago

    Repros Therapeutics Drops on FDA Vote

    Repros Therapeutics saw its shares take a loss on Wednesday after the company provided a key FDA update.

  • 24/7 Wall St.11 months ago

    10 Major Pharma and FDA Catalysts Coming in December

    24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.